MCC-555-induced NAG-1 expression is mediated in part by KLF4

European Journal of Pharmacology

Volumn 637, Issue 1-3, 2010, Pages 30-37

  Cekanova, Maria ^a   Lee, Seong Ho ^a   McEntee, Michael F ^a   Baek, Seung Joon ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

KLF4; MCC 555; NAG 1; Thiazolidinedione

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CIGLITAZONE; CYCLIN D1; KRUPPEL LIKE FACTOR 4; NETOGLITAZONE; NONSTEROID ANTIINFLAMMATORY DRUG ACTIVATED PROTEIN; PIOGLITAZONE; PROSTAGLANDIN J2; ROSIGLITAZONE; TROGLITAZONE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL; CELL STRAIN HCT116; COLON CANCER; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH INHIBITORS; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; NEOPLASM PROTEINS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 77953287799     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.055     Document Type: Article

References (35)

1. Baek S.J., Horowitz J.M., Eling T.E. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J Biol Chem. 2001, 276:33384-33392.
2. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol. 2001, 59:901-908.
3. Baek S.J., Okazaki R., Lee S.H., Martinez J., Kim J.S., Yamaguchi K., Mishina Y., Martin D.W., Shoieb A., McEntee M.F., Eling T.E. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006, 131:1553-1560.
4. Baek S.J., Wilson L.C., Eling T.E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002, 23:425-432.
5. Baek S.J., Wilson L.C., Hsi L.C., Eling T.E. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem. 2003, 278:5845-5853.
6. Baek S.J., Wilson L.C., Lee C.H., Eling T.E. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J. Pharmacol. Exp. Ther. 2002, 301:1126-1131.
7. Balakumar P., Rose M., Ganti S.S., Krishan P., Singh M. PPAR dual agonists: are they opening Pandora's Box?. Pharmacol. Res. 2007, 56:91-98.
8. Bren-Mattison Y., Van Putten V., Chan D., Winn R., Geraci M.W., Nemenoff R.A. Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 2005, 24:1412-1422.
9. Cekanova M., Yuan J.S., Li X., Kim K., Baek S.J. Gene alterations by peroxisome proliferator-activated receptor gamma agonists in human colorectal cancer cells. Int. J. Oncol. 2008, 32:809-819.
10. Chen Z.Y., Tseng C.-C. 15-Deoxy-{Delta}12, 14 prostaglandin J2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor gamma by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer Cells. Mol. Pharmacol. 2005, 68:1203-1213.
11. Chintharlapalli S., Papineni S., Jutooru I., McAlees A., Safe S. Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor gamma agonists in colon cancer cells. Mol. Cancer Ther. 2007, 6:1588-1598.
12. Chintharlapalli S., Papineni S., Liu S., Jutooru I., Chadalapaka G., Cho S.D., Murthy R.S., You Y., Safe S. 2-cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor gamma in colon and pancreatic cancer cells. Carcinogenesis 2007, 28:2337-2346.
13. Choi B.J., Cho Y.G., Song J.W., Kim C.J., Kim S.Y., Nam S.W., Yoo N.J., Lee J.Y., Park W.S. Altered expression of the KLF4 in colorectal cancers. Pathol. Res. Pract. 2006, 202:585-589.
14. Dang D.T., Chen X., Feng J., Torbenson M., Dang L.H., Yang V.W. Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene 2003, 22:3424-3430.
15. Elstner E., Muller C., Koshizuka K., Williamson E.A., Park D., Asou H., Shintaku P., Said J.W., Heber D., Koeffler H.P. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U S A 1998, 95:8806-8811.
16. Foster K.W., Frost A.R., McKie-Bell P., Lin C.Y., Engler J.A., Grizzle W.E., Ruppert J.M. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res. 2000, 60:6488-6495.
17. Foster K.W., Ren S., Louro I.D., Lobo-Ruppert S.M., McKie-Bell P., Grizzle W., Hayes M.R., Broker T.R., Chow L.T., Ruppert J.M. Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth Differ. 1999, 10:423-434.
18. Ghaleb A.M., McConnell B.B., Nandan M.O., Katz J.P., Kaestner K.H., Yang V.W. Haploinsufficiency of Kruppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res. 2007, 67:7147-7154.
19. Katz J.P., Perreault N., Goldstein B.G., Actman L., McNally S.R., Silberg D.G., Furth E.E., Kaestner K.H. Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach. Gastroenterology 2005, 128:935-945.
20. Kumagai T., Ikezoe T., Gui D., O'Kelly J., Tong X.J., Cohen F.J., Said J.W., Koeffler H.P. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin. Cancer Res. 2004, 10:1508-1520.
21. Lee S.-H., Bahn J.H., Choi C.K., Whitlock N.C., English A.E., Safe S., Baek S.J. ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol. Cancer Ther. 2008, 7:3739-3750.
22. Lee S.H., Kim J.S., Yamaguchi K., Eling T.E., Baek S.J. Indole-3-carbinol and 3, 3'-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem. Biophys. Res. Commun. 2005, 328:63-69.
23. Lei P., Abdelrahim M., Safe S. 1, 1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit ovarian cancer cell growth through peroxisome proliferator-activated receptor-dependent and independent pathways. Mol. Cancer Ther. 2006, 5:2324-2336.
24. Li P.X., Wong J., Ayed A., Ngo D., Brade A.M., Arrowsmith C., Austin R.C., Klamut H.J. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J. Biol. Chem. 2000, 275:20127-20135.
25. Qin C., Burghardt R., Smith R., Wormke M., Stewart J., Safe S. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res. 2003, 63:958-964.
26. Rageul J., Mottier S., Jarry A., Shah Y., Theoleyre S., Masson D., Gonzalez F.J., Laboisse C.L., Denis M.G. KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int. J. Cancer 2009, 125:2802-2809.
27. Rowland B.D., Bernards R., Peeper D.S. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 2005, 7:1074-1082.
28. Sarraf P., Mueller E., Smith W.M., Wright H.M., Kum J.B., Aaltonen L.A., de la Chapelle A., Spiegelman B.M., Eng C. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol. Cell 1999, 3:799-804.
29. Shie J.L., Chen Z.Y., Fu M., Pestell R.G., Tseng C.C. Gut-enriched Kruppel-like factor represses cyclin D1 promoter activity through Sp1 motif. Nucleic Acids Res. 2000, 28:2969-2976.
30. Vignati S., Albertini V., Rinaldi A., Kwee I., Riva C., Oldrini R., Capella C., Bertoni F., Carbone G.M., Catapano C.V. Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 2006, 8:851-861.
31. Wei D., Gong W., Kanai M., Schlunk C., Wang L., Yao J.C., Wu T.T., Huang S., Xie K. Drastic down-regulation of Kruppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res. 2005, 65:2746-2754.
32. Yamaguchi K., Cekanova M., McEntee M.F., Yoon J.H., Fischer S.M., Renes I.B., Van Seuningen I., Baek S.J. Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathways. Mol. Cancer Ther. 2008, 7:2779-2787.
33. Yamaguchi K., Lee S.H., Eling T.E., Baek S.J. A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol. Cancer Ther. 2006, 5:1352-1361.
34. Zhang W., Geiman D.E., Shields J.M., Dang D.T., Mahatan C.S., Kaestner K.H., Biggs J.R., Kraft A.S., Yang V.W. The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J. Biol. Chem. 2000, 275:18391-18398.
35. Zhao W., Hisamuddin I.M., Nandan M.O., Babbin B.A., Lamb N.E., Yang V.W. Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene 2004, 23:395-402.